{
  "data": [
    {
      "paragraphs": [
        {
          "qas": [
            {
              "id": "5c8c095e0101eac870000002_001",
              "question": "Which cells secrete lactotransferrin?"
            }
          ],
          "context": "We conclude that lactotransferrin represents a late stage differentiation marker of neutrophils, macrophages and distinct subtypes of dendritic cells."
        },
        {
          "qas": [
            {
              "id": "5c9d18f1ecadf2e73f000033_001",
              "question": "List targets of classical analgesics."
            }
          ],
          "context": "Patient phenotypes in pharmacological pain treatment varies between individuals, which could be partly assigned to their genotypes regarding the targets of classical analgesics (OPRM1, PTGS2) "
        },
        {
          "qas": [
            {
              "id": "5c9d18f1ecadf2e73f000033_002",
              "question": "List targets of classical analgesics."
            }
          ],
          "context": "Morphine is the current gold standard analgesic acting at MOP receptors but produces a range of variably troublesome side-effects, in particular tolerance."
        },
        {
          "qas": [
            {
              "id": "5c961281ecadf2e73f000021_001",
              "question": "List 3 indications for rituximab."
            }
          ],
          "context": "o assess clinical outcomes including imaging findings on computed tomography (CT), pulmonary function testing (PFT), and glucocorticoid (GC) use in patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) treated with rituximab (RTX)."
        },
        {
          "qas": [
            {
              "id": "5c961281ecadf2e73f000021_002",
              "question": "List 3 indications for rituximab."
            }
          ],
          "context": " RIX is the preferred off-label biologic drug for poly- and dermatomyositis in Germany."
        },
        {
          "qas": [
            {
              "id": "5c961281ecadf2e73f000021_003",
              "question": "List 3 indications for rituximab."
            }
          ],
          "context": "Rituximab (RTX) may be a treatment option for children and young people with JIA, although it is not licensed for this indication"
        },
        {
          "qas": [
            {
              "id": "5c961281ecadf2e73f000021_004",
              "question": "List 3 indications for rituximab."
            }
          ],
          "context": " rituximab in children and young people with juvenile idiopathic arthritis"
        },
        {
          "qas": [
            {
              "id": "5c961281ecadf2e73f000021_005",
              "question": "List 3 indications for rituximab."
            }
          ],
          "context": "chronic lymphocytic leukemia (CLL) patients, including the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, phosphatidylinositol-3-kinase (PI3K) delta isoform inhibitor idelalisib combined with rituximab"
        },
        {
          "qas": [
            {
              "id": "5c961281ecadf2e73f000021_006",
              "question": "List 3 indications for rituximab."
            }
          ],
          "context": "rituximab's efficacy has been well-documented in adults with refractory PF"
        },
        {
          "qas": [
            {
              "id": "5c961281ecadf2e73f000021_007",
              "question": "List 3 indications for rituximab."
            }
          ],
          "context": "Rituximab in the management of juvenile pemphigus foliaceus"
        },
        {
          "qas": [
            {
              "id": "5c961603ecadf2e73f000022_001",
              "question": "List off label uses for Rituximab."
            }
          ],
          "context": "Analysis of the data of the GRAID-2 registry for poly- and dermatomyositis.RESULTS: In 22\u00a0of the 23\u00a0patients in the GRAID-2 registry, rituximab (RIX) was administered, while 1\u00a0patient was given tocilizumab as off-label therapy"
        },
        {
          "qas": [
            {
              "id": "5c961603ecadf2e73f000022_002",
              "question": "List off label uses for Rituximab."
            }
          ],
          "context": "Off-label use of rituximab to treat MS patients in Sweden is high"
        },
        {
          "qas": [
            {
              "id": "5c961603ecadf2e73f000022_003",
              "question": "List off label uses for Rituximab."
            }
          ],
          "context": "Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016."
        },
        {
          "qas": [
            {
              "id": "5c961603ecadf2e73f000022_004",
              "question": "List off label uses for Rituximab."
            }
          ],
          "context": "immune thrombocytopenia who do not adequately respond to first-line therapy, there is no clear consensus on which second-line therapy to initiate and when. This situation leads to suboptimal approaches, including prolonged exposure to treatments that are not intended for long-term use (eg, corticosteroids) and overuse of off-label therapies (eg, rituximab) "
        },
        {
          "qas": [
            {
              "id": "5c961603ecadf2e73f000022_005",
              "question": "List off label uses for Rituximab."
            }
          ],
          "context": "Conventional treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN) is associated with damage accrual, hence increased morbidity rate. Off-label use of rituximab (RTX) has shown significant promise in this patient group; however, data are still controversial."
        },
        {
          "qas": [
            {
              "id": "5c961603ecadf2e73f000022_006",
              "question": "List off label uses for Rituximab."
            }
          ],
          "context": "Outcomes of rituximab therapy in refractory lupus: A meta-analysis."
        },
        {
          "qas": [
            {
              "id": "5c890ff475a4a5d219000010_001",
              "question": "Name the uses of Sideritis scardica in traditional medicine."
            }
          ],
          "context": "It is used in traditional medicine as a loosening agent in bronchitis and bronchial asthma; against the common cold and lung emphysema; in the treatment of inflammation, gastrointestinal disorders and coughs; and as an active constituent of dietary supplements for the prevention of anemia."
        },
        {
          "qas": [
            {
              "id": "5c890ff475a4a5d219000010_002",
              "question": "Name the uses of Sideritis scardica in traditional medicine."
            }
          ],
          "context": "A broad range of activities of plant extracts and fractions as antimicrobial, anti-inflammatory, cytotoxic, antioxidant, gastroprotective, antiglioma, and triple monoamine reuptake inhibition as well as cultivation of the species as an approach for conservation of the natural habitats and provision of herb with high and permanent quality has also been presented."
        },
        {
          "qas": [
            {
              "id": "5c979ffcecadf2e73f000028_001",
              "question": "What are 2 organisms that can cause Human toxocariasis?"
            }
          ],
          "context": "Human toxocariasis, a worldwide parasitic disease, is caused by the larval stage of intestinal nematodes of dogs and cats, namely Toxocara canis and Toxocara cati"
        },
        {
          "qas": [
            {
              "id": "5c97f579ecadf2e73f00002a_001",
              "question": "List places in the body where somatostatin is produced."
            }
          ],
          "context": "Somatostatin (SST) is a neuromodulator which is abundant throughout the central nervous system (CNS)"
        },
        {
          "qas": [
            {
              "id": "5c97f579ecadf2e73f00002a_002",
              "question": "List places in the body where somatostatin is produced."
            }
          ],
          "context": "Somatostatin (SST) is abundantly produced by the human retina, and the main source is the retinal pigment epithelium (RPE)."
        },
        {
          "qas": [
            {
              "id": "5c97f579ecadf2e73f00002a_003",
              "question": "List places in the body where somatostatin is produced."
            }
          ],
          "context": "Somatostatin (Som), one of the most concentrated neuropeptides in the brain, is highly expressed in the olfactory bulb (OB)"
        },
        {
          "qas": [
            {
              "id": "5c97f579ecadf2e73f00002a_004",
              "question": "List places in the body where somatostatin is produced."
            }
          ],
          "context": "The production of somatostatin interneurons in the olfactory bulb is regulated by the transcription factor sp8"
        },
        {
          "qas": [
            {
              "id": "5c97f579ecadf2e73f00002a_005",
              "question": "List places in the body where somatostatin is produced."
            }
          ],
          "context": "Somatostatin expression in human hair follicles and its potential role in immune privilege"
        },
        {
          "qas": [
            {
              "id": "5c97f579ecadf2e73f00002a_006",
              "question": "List places in the body where somatostatin is produced."
            }
          ],
          "context": "The kinetics of insulin, glucagon and somatostatin release was studied in human pancreatic islets."
        },
        {
          "qas": [
            {
              "id": "5c97f579ecadf2e73f00002a_007",
              "question": "List places in the body where somatostatin is produced."
            }
          ],
          "context": "Glucose generates coincident insulin and somatostatin pulses and antisynchronous glucagon pulses from human pancreatic islets."
        },
        {
          "qas": [
            {
              "id": "5c9f79c3ecadf2e73f00003d_001",
              "question": "What are the 3 types of immunoglobulin heavy chain containing antibodies found in human breast milk?"
            }
          ],
          "context": "This is a descriptive cross-sectional study of a convenience sample of 67 donated colostrum samples at different days after delivery, both raw and pasteurized. Antibody profiles were analyzed at different times during breastfeeding, and total and specific antibodies (IgM, IgA, and IgG subclasses)"
        },
        {
          "qas": [
            {
              "id": "5c9fb583ecadf2e73f000042_001",
              "question": "What are 5 key questions in human performance modeling?"
            }
          ],
          "context": "the five key questions of human performance modeling: 1) Why we build models of human performance; 2) What the expectations of a good human performance model are; 3) What the procedures and requirements in building and verifying a human performance model are; 4) How we integrate a human performance model with system design; and 5) What the possible future directions of human performance modeling research are. "
        },
        {
          "qas": [
            {
              "id": "5ca64b5becadf2e73f000051_001",
              "question": "List the ERM proteins."
            }
          ],
          "context": "ezrin/radixin/moesin (ERM) proteins"
        },
        {
          "qas": [
            {
              "id": "5ca64b5becadf2e73f000051_002",
              "question": "List the ERM proteins."
            }
          ],
          "context": "ezrin, radixin and moesin (ERM proteins)"
        },
        {
          "qas": [
            {
              "id": "5ca64b5becadf2e73f000051_003",
              "question": "List the ERM proteins."
            }
          ],
          "context": "Ezrin/radixin/moesin (ERM) proteins"
        },
        {
          "qas": [
            {
              "id": "5c9007460101eac870000012_001",
              "question": "Name three binding partners of cofilin 2."
            }
          ],
          "context": "Cofilin-2 (Cfl2) was identified as one of the potential targets of miR-301a using prediction databases, which we validated by luciferase assay and mutation of predicted binding sites."
        },
        {
          "qas": [
            {
              "id": "5c9007460101eac870000012_002",
              "question": "Name three binding partners of cofilin 2."
            }
          ],
          "context": "Cofilin weakly interacts with 14-3-3 and therefore can only indirectly participate in regulation of cell motility by small heat shock protein HspB6 (Hsp20)."
        },
        {
          "qas": [
            {
              "id": "5c9007460101eac870000012_003",
              "question": "Name three binding partners of cofilin 2."
            }
          ],
          "context": "In contrast to other isoforms, cofilin-2 efficiently binds and disassembles both ADP- and ATP/ADP-Pi-actin filaments. We mapped surface-exposed cofilin-2-specific residues required for ATP-actin binding and propose that these residues function as an \"actin nucleotide-state sensor\" among ADF/cofilins."
        },
        {
          "qas": [
            {
              "id": "5c990afbecadf2e73f000030_001",
              "question": "List proteins with RING domain."
            }
          ],
          "context": " The RING domain of RING1 was required for its E3 Ub ligase activity."
        },
        {
          "qas": [
            {
              "id": "5c990afbecadf2e73f000030_002",
              "question": "List proteins with RING domain."
            }
          ],
          "context": " The TRIM proteins are classically characterized by the presence of an amino-terminal RING domain and a B-box domain followed by a coiled coil domain"
        },
        {
          "qas": [
            {
              "id": "5c990afbecadf2e73f000030_003",
              "question": "List proteins with RING domain."
            }
          ],
          "context": "the detailed mechanism by which the TRAF6 RING dimer promotes ubiquitin transfer was unknown. "
        },
        {
          "qas": [
            {
              "id": "5c990afbecadf2e73f000030_004",
              "question": "List proteins with RING domain."
            }
          ],
          "context": "RING ubiquitin E3 ligases enclose a RING domain for ubiquitin ligase activity"
        },
        {
          "qas": [
            {
              "id": "5c990afbecadf2e73f000030_005",
              "question": "List proteins with RING domain."
            }
          ],
          "context": " UHRF1 RING domain"
        },
        {
          "qas": [
            {
              "id": "5c990afbecadf2e73f000030_006",
              "question": "List proteins with RING domain."
            }
          ],
          "context": " MARCH7, a RING domain-containing ubiquitin E3 ligase,"
        },
        {
          "qas": [
            {
              "id": "5c990afbecadf2e73f000030_007",
              "question": "List proteins with RING domain."
            }
          ],
          "context": "Seven in absentia (SINA) protein is one subgroup of ubiquitin ligases possessing an N-terminal cysteine-rich really interesting new gene (RING) domain,"
        },
        {
          "qas": [
            {
              "id": "5c990afbecadf2e73f000030_008",
              "question": "List proteins with RING domain."
            }
          ],
          "context": "The BRCA1 RING domain is a ubiquitin ligase"
        }
      ],
      "title": "BioASQ6b"
    }
  ],
  "version": "BioASQ6b"
}